Skip to main content

Table 3 Stratified analyses for the evaluation of heterogeneity in studies with real-time PCR assay

From: Diagnostic accuracy of in-house real-time PCR assay for Mycobacterium tuberculosis: a systematic review and meta-analysis

Subgroup (Number of studies) Summary diagnostic odds ratio (95% CI)a Chi2 square test of heterogeneity P value for heterogeneityb
Study design
 Cross-sectional (10) 403.18 (120.05–1354.05) 36.66 < 0.001
 Case-control (8) 73.86 (20.40–267.48) 34.01 < 0.001
Target sequence
 IS6110 (11) 144.74 (51.24–408.86) 39.39 < 0.001
 Other target (7) 297.17 (30.22–2921.73) 66.27 < 0.001
Specimen type
 Respiratory (11) 598.12 (269.12–1329.32) 19.09 0.039
 Non-respiratory (5) 12.39 (6.67–22.73) 3.57 0.468
 Both (2) 202.47 (64.68–633.83) 0.00 0.944
Region of study
 TB high-burden country (8) 281.86 (37.69–2107.75) 90.46 < 0.001
 Other country (10) 160.73 (72.80–354.83) 15.17 0.086
Quality of study
 High-quality (7) 926.97 (303.59–2830.38) 12.83 0.046
 Medium-quality (8) 76.77 (22.98–256.50) 26.65 < 0.001
 Low-quality (3) 72.35 (4.47–1170.04) 19.07 < 0.001
  1. aRandom effects model
  2. bchi-square or Fisher’s exact test for heterogeneity; high-quality study: a study that had no domain with a high risk of bias and no domain with high applicability concerns; medium/moderate-quality study: a study that had domain with a unclear risk of bias or domain with unclear applicability concerns; low-quality study: a study that had a domain with a high risk of bias and domain with high applicability concerns